Knowledge Library
Patient-Derived Xenograft (PDX) Tumor Models
One of the largest collection of Patient-Derived Xenograft (PDX) Tumor Models in Asia with gene expression/mutation profiling 1200 PDX models Collection of PDX models prevalent in Asia 800+ PDX models with genetic profiling Searchable online database with mobile APP Integrated online database for PDX, CDX & Syngeneic tumor models with mobile App PDX with oncogene …Read More >
Immuno-Oncology Services
Immuno-oncology Platform An outstanding platform to enable cancer immunotherapy with one stop service: Immunological function assessment TIL analysis – Flowcytometry, Multiplex IF and Cytex Animal models – Syngeneic and humanized models Immune profiling by NGS – Single Cell RNAseq, Mutation burden and TCR/BCR repertoire Clinical biomarker services – CAP certification and GCP compliance
Cell Line-Derived Xenograft (CDX) Tumor Models
A large collection of cell line-derived xenograft (CDX) tumor models 215 validated models, SOC data available World leading imaging based orthotopic/metastatic CDX platform 28 models covering 16 tumor types
WuXi Oncology and Immuno-Oncology Services
Integrated Oncology and Immuno-oncology Platform to Enable Translational Science from Drug Discovery to Clinical Biomarker Oncology Services CRISPR/Cas9 Gene Editing In Vitro Assay and HTS Tumor models Tumor Cell Panel and Screening Immunology and Immuno-oncology Platform Clinical Biomarker Immunology Services Ligand-receptor binding assays Cellular functional assays Assays for innate immunity pathways: macrophage, MDSC, NK, DC, …Read More >
Virology and Viral Vector Platforms
WuXi virology platforms: Immunology, Anti viral, Viral Vector, Oligo-nucleotide, Clinical and Immunology in vitro screening and profiling in vivo efficacy clinical virology Liver-specific viruses | Respiratory viruses | Herpes viruses | Other viruses
WuXi AppTec in vitro Safety Pharmacology Profiling
Comprehensive in vitro off-target screening services Safety-related drug failure is a major challenge for the pharmaceutical industry. Approximately 75% of adverse drug reactions (ADRs) are dose-dependent, related to a pharmacological action of the drug, and predictable. The interactions of drugs with off-target proteins have conventionally been viewed as undesirable ‘promiscuity’, responsible for unwanted side effects. …Read More >
In Vitro Toxicity Services
Identify Potential Liability Issues in the Early Stages of Drug Discovery Drug-induced toxicity is a primary cause of failure for drug candidates during preclinical and clinical testing and a significant reason for approved drugs being removed from the market. Initial toxicity tests, which largely rely on animal studies, are essential during the nonclinical phase of …Read More >
HBV Discovery Services
A Platform Supporting HBV Drug Discovery A broad assay platform for the discovery of agents for the treatment of chronic HBV infection. Services for assay establishment and validation, compound screening and profiling, and support of preclinical studies and clinical trials. Drug screening using HBV producing cell lines HBV infectious assays Reporter assays Core protein expression …Read More >
Clinical Virology
Clinical Virology and Advanced Therapy Platforms Research Services: CAP Accredited Molecular Testing Laboratory Genetics and Biomarker Platform HBV Genotyping Assays HBV Serology Assays HBV Phenotyping Assays Immunological Assays Other Assays: Oncolytic | CAR-T/TCR-T Particular Solutions Clinical virology: Viral load, sequencing, genotyping, TCID50, phenotyping, virus isolation and characterization, serology Vaccines: Advanced therapies (Viral vector and cell therapies): …Read More >